Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Manosuthi, Weerawat ^a,b   Mankatitham, Wiroj ^a   Lueangniyomkul, Aroon ^a   Prasithsirikul, Wisit ^a   Tantanathip, Preecha ^a   Suntisuklappon, Busakorn ^a   Narkksoksung, Anongnuch ^a   Nilkamhang, Samruay ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PHOSPHORUS; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; URIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; URIC ACID BLOOD LEVEL; URINALYSIS;

EID: 77957680444     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-37     Document Type: Article

References (28)

1. Guideline for the use of antiretroviral agents in HIV- infected adults and adolescents. 2009, Department of heath and human services and the Henry J. Kaiser family foundation.
2. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-70. 10.1001/jama.300.5.555, 18677028.
3. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007, 21:1273-81. 10.1097/QAD.0b013e3280b07b33, 17545703.
4. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009, 23:1547-56. 10.1097/QAD.0b013e32832cbcc2, 19542866.
5. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005, 40:1194-8. 10.1086/428840, 15791522.
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201. 10.1001/jama.292.2.191, 15249568.
7. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004, 37:1489-95. 10.1097/01.qai.0000138983.45235.02, 15602127.
8. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008, 22:2155-63. 10.1097/QAD.0b013e3283112b8e, 18832879.
9. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9:563-608. 10.1111/j.1468-1293.2008.00636.x, 18826546.
10. Scaling up Antiretroviral Therapy in Resource-limited Settings Treatment Guidelines for a public Health Approach. 2003, Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), Scaling up Antiretroviral Therapy in Resource-limited Settings.
11. Labarga P, Medrano J, Seclen E, et al. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS 2010, 24:777-9. 10.1097/QAD.0b013e3283322895, 20168201.
12. Weberschock T, Gholam P, Hueter E, Flux K, Hartmann M. Long-term Efficacy and Safety of Once-daily Nevirapine in Combination with Tenofovir and Emtricitabine in the Treatment of HIV-infected Patients: A 72-week Prospective Multicenter Study (TENOR-Trial). Eur J Med Res 2009, 14:516-9.
13. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009, 48:1752-9. 10.1086/599114, 19438397.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-70.
15. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004, 43:595-612. 10.2165/00003088-200443090-00003, 15217303.
16. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003, 23:29-43. 10.1592/phco.23.1.29.31915, 12523458.
17. Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?. J Infect 2006, 52:335-8. 10.1016/j.jinf.2005.07.020, 16176835.
18. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010, 17:72-82. 10.1053/j.ackd.2009.07.009, 20005491.
19. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004, 18:1074-6. 10.1097/00002030-200404300-00019, 15096814.
20. Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr 2005, 38:301-4.
21. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010, 24:525-34. 10.1097/QAD.0b013e3283333680, 20139752.
22. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006, 42:283-90. 10.1086/499048, 16355343.
23. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read 2009, 19:114-21.
24. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999, 27:1488-95.
25. FDA Viramune Prescribing Information 9. 06/24/08, Accessed 03/12/09, FDA Viramune Prescribing Information., http://www.fda.gov/cder/foi/label/2008/020636s027,020933s017lbl.pdf
26. Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007, 12:267-72.
27. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009, 48:e108-16. 10.1086/598507, 19400747.
28. Wever K, van Agtmael MA, Carr A. Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men. J Acquir Immune Defic Syndr 2010, 55:78-81. 10.1097/QAI.0b013e3181d05579, 20173649.